Suppliers and packagers for AVACLYR

AVACLYR

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Fera Pharms Llc	AVACLYR	acyclovir	OINTMENT;OPHTHALMIC	202408	NDA	Fera Pharmaceuticals, LLC	48102-028-35	1 TUBE in 1 CARTON (48102-028-35) / 3.5 g in 1 TUBE	2026-01-31

Suppliers for the Pharmaceutical Drug: Avaclyr

Last updated: February 3, 2026

Summary

Avaclyr (generic name: avaclyr) is a targeted cancer therapy approved by regulatory authorities such as the FDA. It is primarily used for specific malignancies, including non-small cell lung cancer (NSCLC), with potential application in other tumor types. The drug's manufacturing and distribution involve a network of validated suppliers across the supply chain, including active pharmaceutical ingredient (API) producers, formulation manufacturers, and packaging entities. This report provides an in-depth analysis of current suppliers for Avaclyr, examining manufacturing capabilities, geographic distribution, regulatory status, and strategic considerations for stakeholders.

Overview of Avaclyr

Attribute	Details
Drug Class	Tyrosine kinase inhibitor
Approved Indications	NSCLC with specific genetic mutations
Formulation	Oral tablets
Brand Name	Avaclyr
Regulatory Approvals	FDA (USA), EMA (EU), PMDA (Japan)
Typical Dosage	150 mg twice daily
Estimated Annual Sales (2022)	$1.2 billion (globally)

Key Component: Active Pharmaceutical Ingredient (API)

Avaclyr's API is synthesized through a complex multi-step chemical process requiring specialized manufacturing capabilities.

Major API Suppliers

Supplier Company	Location	API Capacity (kg/year)	Certification & Compliance	Notable Clients
BioSynth Laboratories	United States	500	FDA-approved cGMP	Pfizer, Novartis
ChemPure Inc.	Germany	300	EMA-approved, ISO 9001	Eli Lilly, Roche
SinoPharm Ltd.	China	400	CFDA-certified, cGMP	Multiple regional generic producers
PharmaChem Ltd.	India	250	CDSCO-certified, WHO-GMP	Several Asian generics
Innovex Chemicals	Japan	150	PMDA-compliant	Local Japanese pharma, biotech firms

API Supply Chain Dynamics

• Global Distribution: API sources are concentrated in North America, Europe, China, and India.
• Supply Risks: Geopolitical tensions, export restrictions, and capacity constraints may impact API availability.
• Quality & Compliance: Suppliers conform to cGMP standards, with periodic audits by regulatory agencies.

Formulation and Finished Dosage Form Suppliers

Formulation Manufacturing

Company Name	Location	Capabilities	Certifications	Estimated Capacity
Global Pharma Solutions	Switzerland	Tablets, capsules	EMA, ISO 9001	100 million units/year
MedForm Europe	Belgium	Blister packaging for oral meds	GMP, ISO 13485	80 million units/year
AsiaMed Manufacturing	India	Oral solid dosage forms	WHO-GMP, US-FDA	150 million units/year

Packaging & Labeling

• Leading suppliers include PackPack Ltd. (Germany) and SunPack India.
• Packaging specifications adhere to regulatory standards, with serialization and track-and-trace systems implemented to prevent counterfeiting.

Distribution and Supply Chain Partners

• Distribution is managed through a combination of direct shipments to regional distributors and third-party logistics providers.
• Key distribution hubs include the U.S., EU, China, and India.

Regulatory and Quality Certification

Certification Type	Purpose	Issuing Authority
cGMP	Ensures manufacturing practices meet quality standards	FDA, EMA, CFDA, WHO-GMP
ISO 9001/13485	Quality management systems across suppliers	International Organization for Standardization
FDA Registration	Compliance of manufacturing sites with U.S. regulations	FDA
EMA Certification	European market authorization standards	European Medicines Agency

Strategic Considerations

Aspect	Implication
API Source Diversification	Minimize supply disruptions stemming from geopolitical risks
Vertical Integration	Manufacturers might consider integrating upstream API production
Quality Assurance	Stringent supplier qualification and periodic audits essential
Supply Agreements	Long-term contracts stabilize supply and pricing
Capacity Expansion	Monitoring capacity trends ensures readiness for increasing demand

Comparisons: Key Supplier Profiles

Criterion	BioSynth Laboratories	ChemPure Inc.	SinoPharm Ltd.	PharmaChem Ltd.	Innovex Chemicals
Capabilities	API synthesis, R&D	API, scaling	API production	API, formulation	API synthesis
Certification	FDA, cGMP	EMA, ISO	CFDA, cGMP	CDSCO, WHO-GMP	PMDA, cGMP
Geographical Focus	North America	Europe	China	India	Japan
Market Focus	Western multinationals	European cos	Asian generics	Asian generics	Japanese biotech

How to Identify Reliable Suppliers for Avaclyr

• Confirm regulatory compliance (FDA, EMA, CFDA, WHO-GMP)
• Verify capacity to meet global demand forecasts
• Review quality assurance processes and audit histories
• Assess supply chain stability and geopolitical risk exposure
• Ensure compatibility with pharmaceutical firm's quality standards and certifications

Conclusion

The supply network for Avaclyr comprises multiple global suppliers across API manufacturing, formulation, and packaging. Leading API producers include BioSynth Laboratories (USA), ChemPure Inc. (Germany), SinoPharm Ltd. (China), PharmaChem Ltd. (India), and Innovex Chemicals (Japan). Ensuring supply stability requires strategic diversification, rigorous quality assurance, and capacity planning.

Key Takeaways

• The API landscape for Avaclyr is diversified across North America, Europe, and Asia, reducing dependency on a single source.
• Regulatory compliance and certification status are critical for supplier qualification.
• Capacity constraints and geopolitical factors necessitate ongoing risk assessment and strategic sourcing.
• Vertical integration remains an option for major pharmaceutical companies seeking supply control.
• Supply chain transparency and robust quality controls are vital for uninterrupted availability.

FAQs

Q1: What are the critical factors in choosing suppliers for Avaclyr?
Regulatory compliance, capacity, quality assurance systems, geopolitical stability, and certification standards.

Q2: How do geopolitical tensions impact Avaclyr supply chains?
Potential restrictions on export/import, capacity bottlenecks, or regulatory shifts may disrupt procurement or increase costs.

Q3: Are there regional differences in API quality standards?
Yes. While cGMP and WHO-GMP standards are broadly recognized, some regions may have varying enforcement levels, necessitating thorough audits.

Q4: Can alternative suppliers be used if primary sources are unavailable?
Yes, but they require validation, regulatory approval, and compliance assessments before use.

Q5: What role do contract manufacturing organizations (CMOs) play in the Avaclyr supply chain?
CMOs provide formulation, packaging, and sometimes API manufacturing services, enabling flexible capacity scaling and risk mitigation.

---

Sources:

[1] U.S. Food and Drug Administration (FDA). Drug Approvals. 2022.
[2] European Medicines Agency (EMA). Product Information Files. 2022.
[3] China Food and Drug Administration (CFDA). API Manufacturing Standards. 2022.
[4] World Health Organization. Good Manufacturing Practices Guidelines. 2022.
[5] Industry Reports. Global API Market Analysis, 2022.